CD8A and neoplasm: Likewise, tumor-bearing mice treated with pBI-11 or pBI-12 generated significantly higher percentages of HPV18 E6-specific CD8+ T cell-mediated immune responses than mice treated with pBI-10.1 (Fig. 5C).